Hydroxyurea in the treatment of HIV-1

Citation
Ma. Gibbs et Sj. Sorensen, Hydroxyurea in the treatment of HIV-1, ANN PHARMAC, 34(1), 2000, pp. 89-93
Citations number
21
Categorie Soggetti
Pharmacology
Journal title
ANNALS OF PHARMACOTHERAPY
ISSN journal
10600280 → ACNP
Volume
34
Issue
1
Year of publication
2000
Pages
89 - 93
Database
ISI
SICI code
1060-0280(200001)34:1<89:HITTOH>2.0.ZU;2-4
Abstract
OBJECTIVE: To describe the role of hydroxyurea in the treatment of HIV-1. DATA SOURCES: Published clinical studies using hydroxyurea in HIV treatment were accessed through MEDLINE (January 1994-March 1999) and conference abs tracts. All relevant studies were evaluated. DATA SYNTHESIS: Adherence, expense, and resistance limit the pharmacotherap eutic options in the management of patients with HIV. Hydroxyurea may be an alternative to conventional HIV treatments. CONCLUSIONS: Several potential advantages of adding hydroxyurea to antiretr oviral treatment regimens include the drug's well-documented toxicity, conv enient dosing, good tolerability and low cost, and its unique mechanism of action. Hydroxyurea may have synergistic effects that prove promising in in itial and salvage therapy antiretroviral regimens. Larger, well-controlled clinical studies are needed to adequately define the role of hydroxyurea in the treatment of HIV.